hVIVO Share News (HVO)

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

hVIVO swings to profit and commences annual dividends as outlook rosy

(Alliance News) - hVIVO PLC on Tuesday launched an annual dividend policy, as it swung to profit on the back of higher revenue and a tax credit.

Hvivo unveils record results and bullish growth targets

(Sharecast News) - Shares in AIM-listed Hvivo dipped on Tuesday despite the infectious and respiratory disease treatment firm reporting a record year across all financial and operational metrics, as well as ambitious revenue targets for the coming years.

European Green Transition starts trading on London's AIM market

(Alliance News) - European Green Transition PLC on Monday started trading on the AIM market of the London Stock Exchange, in a bid to contribute to its existing green economy projects.

UK earnings, trading statements calendar - next 7 days

Investment firm European Green Transition plans listing on AIM

(Alliance News) - European Green Transition Ltd on Monday said it plans to launch its initial public offering on London's AIM market in early April.

IN BRIEF: hVIVO Chair and non-exec director sell 30.0 million shares

hVIVO PLC - London-based contract research organisation testing vaccines for infectious and respiratory diseases - Confirms two shareholders, Chair Cathal Friel and Non-Executive Director Brendan Buckley have sold a total around 30.0 million shares in company in a placing at 28 pence per share. Sale represents around 4.4% of the company's share capital. Friel sells around 26.0 million shares with a resulting holding of 3.1%. Buckley sells around 4.0 million shares with a resulting holding of 0.6%. The selling shareholders have agreed with Cavendish and Peel Hunt not to dispose of any further shares for a period of 12 months without the prior written consent of Cavendish and Peel Hunt.

IN BRIEF: hVIVO directors to sell total of 14 million shares

hVIVO PLC - London-based contract research organisation testing vaccines for infectious and respiratory diseases - Announces that certain directors intend to sell at least 14.0 million shares in total, at 28 pence each. Placing shares represent approximately 25% of the directors' current shareholding. Selling shareholders include investment vehicles of Chair Cathal Friel, and his spouse Pamela Iyer.

hVIVO shares up after "record year" across all metrics

(Alliance News) - hVIVO PLC on Tuesday set a new revenue target of GBP100 million by 2028, after a "strong financial and operational performance" last year.

hVIVO inks GBP6.3 million deal to test common cold treatment

(Alliance News) - hVIVO PLC on Tuesday said it signed a contract worth GBP6.3 million to test a potential treatment for the common cold.

hVIVO secures £6.3m contract with biotech client

(Sharecast News) - Infectious and respiratory disease study group hVIVO has inked a £6.3m contract with an unnamed biotechnology client to test an antiviral candidate using its common cold virus human challenge study model.

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Sunday share tips: hVivo and On the Beach

(Sharecast News) - Drug-testing specialist hVivo was one of the top tips for 2023 from The Daily Mail's Midas column, but the paper still reckons there's further to go despite the stock doubling in price over the year.

hVIVO signs deal to test RSV antiviral drug candidate with study model

(Alliance News) - hVIVO PLC on Wednesday said it signed a deal with an unnamed existing client to test a respiratory syncytial virus antiviral drug candidate using its study model.